Park Avenue Securities’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $1.14M | Buy |
|
|||||
|
2025
Q2 | $1.02M | Buy |
|
|||||
|
2025
Q1 | $783K | Buy |
|
|||||
|
2024
Q4 | $966K | Buy |
|
|||||
|
2024
Q3 | $662K | Sell |
|
|||||
|
2024
Q2 | $1.37M | Buy |
|
|||||
|
2024
Q1 | $1.32M | Buy |
|
|||||
|
2023
Q4 | $1.25M | Buy |
|
|||||
|
2023
Q3 | $1.01M | Buy |
|
|||||
|
2023
Q1 | – | Sell |
|
|||||
|
2022
Q4 | $1.02M | Buy |
|
|||||
|
2022
Q3 | $905K | Sell |
|
|||||
|
2022
Q2 | $899K | Buy |
|
|||||
|
2022
Q1 | $742K | Buy |
|
|||||
|
2021
Q4 | $328K | Sell |
|
|||||
|
2021
Q3 | $554K | Buy |
|
|||||
|
2021
Q2 | $507K | Buy |
|
|||||
|
2021
Q1 | $397K | Buy |
|
|||||
|
2020
Q4 | $325K | Buy |
|
|||||
|
2020
Q3 | $296K | Buy |
|
|||||
|
2020
Q2 | $233K | Buy |
|